KAILUA-KONA, Hawaii--(BUSINESS WIRE)--Oct. 7, 2002-- Studies Show BioAstin(R) Relieves Pain and Improves Performance in Patients with Rheumatoid Arthritis and Carpel Tunnel Syndrome Cyanotech Corporation (Nasdaq:CYAN), the world leader in producing high-value, natural products from microalgae, today announced that the results of two separate clinical trials on the use of BioAstin(R) for rheumatoid arthritis (RA) and carpel tunnel syndrome (CTS) were presented at the scientific meeting of the American College of Nutrition in San Antonio, Texas on October 4, 2002.
Originally reported by Cyanotech in summary in May 2002, the clinical trials were conducted by Dr. Gene Spiller at the Health Research Studies Center in Los Altos, California, and were double-blinded, placebo-controlled studies. The RA clinical trial involved 21 patients with a group of 14 randomized patients consuming three BioAstin gelcaps daily with each meal for eight weeks and seven randomized patients consuming a placebo. The CTS clinical trial involved 20 patients with a group of 13 randomized patients consuming three BioAstin gelcaps daily with each meal for eight weeks and seven randomized patients consuming a placebo. In the RA study, subjects completed a health assessment questionnaire at the beginning of the study and after four and eight weeks. In the CTS study, subjects completed a Symptom Severity Survey at the same time frames.
The RA clinical trial showed a statistically significant improvement in symptoms of RA in patients who consumed BioAstin compared to the placebo group. The CTS clinical trial showed a trend toward decreased wrist pain for patients consuming BioAstin compared to the placebo group. The RA study concluded that BioAstin may be an important addition to RA treatment allowing patients to have less pain and more satisfaction with their ability to perform their usual activities. The CTS study concluded that BioAstin may be an effective treatment for CTS allowing patients to suffer less daytime pain with a shorter duration of pain. The clinical trials were followed by open label studies with volunteers from each trial. Preliminary results from the open label study are very positive.
"These studies, combined with the results of another study showing positive effects from using BioAstin on knee soreness, adds to the growing body of scientific evidence that BioAstin offers a viable natural alternative for persons who suffer from a variety of joint pains," said Gerald R. Cysewski, PhD., president and CEO of Cyanotech. "These results should provide the major dietary supplement companies that are beginning to include, or plan to include, BioAstin in their products with further scientific support to develop products for the $6.8 billion joint health market."
Dr. Cysewski noted that many patients in both trials began purchasing BioAstin after the study periods to continue taking the product.
The active ingredient in BioAstin, natural astaxanthin, has been shown to be a potent antioxidant over 500 times stronger than vitamin E and 10 times stronger than beta carotene. Joint pain and joint inflammation can be caused by oxidative damage as a result of free radicals. Free radicals are generated from exposure to toxic pollutants or by the body itself as part of an immune response. The potent antioxidant properties of BioAstin may help neutralize these free radicals and minimize oxidative damage to joints.
-- Cyanotech Corporation, the world's leader in microalgae technology, produces high-value natural products from microalgae, and is the world's largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(R) natural astaxanthin, a powerful antioxidant with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture and animal feed industries; Spirulina Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina and BioAstin are sold directly online through www.nutrex-hawaii.com and www.bioastinxp.com as well as through resellers worldwide in over 30 countries. Corporate and product information is available at www.cyanotech.com
SAFE HARBOR -- Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to our largest customers, weather patterns, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation, and other factors more fully detailed in the company's recent quarterly 10-Q and annual 10-K filings with the Securities and Exchange Commission.